| Name | Title | Contact Details |
|---|---|---|
John Lamoureux |
Director, Global IT Infrastructure and Security | Profile |
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
Ria Healths at-home program uses technology, anti-craving medication & online coaching to help you reduce or quit drinking. Change your habits today.
Cosmo Bio USA is a company that provides quality life science products from leading Japanese manufacturers to laboratories, research institutes, life science education and testing organizations throughout North America.
Establishing a new standard of care, where all patients in general surgery, gynecology and urology have access to optimal minimally invasive care.
A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.